会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Compositions and Methods for Bone Formation and Remodeling
    • 骨形成和重塑的组成和方法
    • US20060198791A2
    • 2006-09-07
    • US10849067
    • 2004-05-19
    • Dianqing WuYazhou ZhangPeng LiuXiaofeng LiJie ZhangJufang ShanDean Engelhardt
    • Dianqing WuYazhou ZhangPeng LiuXiaofeng LiJie ZhangJufang ShanDean Engelhardt
    • A61K9/68A61K7/28G01N33/53G06F19/00G01N33/48G01N33/50
    • G01N33/6893A61K38/00G01N33/6887G01N2500/00G01N2800/10G01N2800/108
    • Abstract of the DisclosureThe mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors’ transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that osteoblast cells produce autocrine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt.
    • 公开摘要研究了Wnt共同受体LRP5的高骨量(HBM)突变(G171V)调节规范Wnt信号传导的机制。 以前显示突变可以降低Dkk蛋白-1介导的拮抗作用,这表明G171位于第一个YWTD重复结构域可能是Dkk蛋白介导的拮抗作用的原因。 然而,我们发现第三个YWTD重复,但不是第一个重复结构域,是DKK1介导的拮抗作用所必需的。 相反,我们发现G171V突变破坏了LRP5与Mesd的相互作用,Mesd是共受体转运到细胞表面所需的LRP5 / 6的伴侣蛋白,导致细胞表面上较少的LRP5分子。 尽管细胞表面LRP5分子水平的降低导致旁分泌范例中Wnt信号传导的降低,但突变似乎不影响共表达Wnt在自分泌范式中的活性。 连同观察到成骨细胞产生自分泌的正常Wnt,Wnt7b,并且该骨细胞产生旁分泌的Dkk1,我们认为G171V突变可能通过减少旁分泌Dkk1靶向拮抗的数目而引起成骨细胞中Wnt活性的增加,而不影响 自分泌Wnt的活性。
    • 2. 发明授权
    • Compositions and methods for bone formation and remodeling
    • 用于骨形成和重塑的组合物和方法
    • US08637506B2
    • 2014-01-28
    • US10849067
    • 2004-05-19
    • Dianqing WuYazhou ZhangPeng LiuXiaofeng LiJie ZhangJufang ShanDean Engelhardt
    • Dianqing WuYazhou ZhangPeng LiuXiaofeng LiJie ZhangJufang ShanDean Engelhardt
    • A61K31/535C07C50/18
    • G01N33/6893A61K38/00G01N33/6887G01N2500/00G01N2800/10G01N2800/108
    • The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that osteoblast cells produce autocrine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt.
    • 研究了Wnt共同受体LRP5的高骨量(HBM)突变(G171V)调节规范Wnt信号传导的机制。 以前显示突变可以降低Dkk蛋白-1介导的拮抗作用,这表明G171位于第一个YWTD重复结构域可能是Dkk蛋白介导的拮抗作用的原因。 然而,我们发现第三个YWTD重复,但不是第一个重复结构域,是DKK1介导的拮抗作用所必需的。 相反,我们发现G171V突变破坏了LRP5与Mesd的相互作用,Mesd是共受体转运到细胞表面所需的LRP5 / 6的伴侣蛋白,导致细胞表面上较少的LRP5分子。 尽管细胞表面LRP5分子水平的降低导致旁分泌范例中Wnt信号传导的降低,但突变似乎不影响共表达Wnt在自分泌范式中的活性。 连同观察到成骨细胞产生自分泌的正常Wnt,Wnt7b,并且该骨细胞产生旁分泌的Dkk1,我们认为G171V突变可能通过减少旁分泌Dkk1靶向拮抗的目标数量引起成骨细胞中Wnt活性的增加,而不会影响 自分泌Wnt的活性。
    • 3. 发明申请
    • Compositions and methods for bone formation and remodeling
    • 用于骨形成和重塑的组合物和方法
    • US20050196349A1
    • 2005-09-08
    • US10849067
    • 2004-05-19
    • Dianqing WuYazhou ZhangPeng LiuXiaofeng LiJie ZhangJufang ShanDean Engelhardt
    • Dianqing WuYazhou ZhangPeng LiuXiaofeng LiJie ZhangJufang ShanDean Engelhardt
    • A61K9/68G01N33/48G01N33/50G01N33/53G01N33/68G06F19/00A61K7/28
    • G01N33/6893A61K38/00G01N33/6887G01N2500/00G01N2800/10G01N2800/108
    • The mechanism by which the high bone mass (HBM) mutation (G171V) of the Wnt coreceptor LRP5 regulates the canonical Wnt signaling was investigated. The mutation was previously shown to reduce Dkk protein-1-mediated antagonism, suggesting that the first YWTD repeat domain where G171 is located may be responsible for Dkk protein-mediated antagonism. However, we found that the third YWTD repeat, but not the first repeat domain, is required for DKK1-mediated antagonism. Instead, we found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperon protein for LRP5/6 that is required for the coreceptors' transport to cell surfaces, resulting in less LRP5 molecules on the cell surface. Although the reduction in the level of cell surface LRP5 molecules led to a reduction in Wnt signaling in a paracrine paradigm, the mutation did not appear to affect the activity of coexpressed Wnt in an autocrine paradigm. Together with the observation that osteoblast cells produce autocrine canonical Wnt, Wnt7b, and that osteocytes produce paracrine Dkk1, we believe that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine Dkk1 to antagonize without affecting the activity of autocrine Wnt.
    • 研究了Wnt共同受体LRP5的高骨量(HBM)突变(G171V)调节规范Wnt信号传导的机制。 以前显示突变可以降低Dkk蛋白-1介导的拮抗作用,这表明G171位于第一个YWTD重复结构域可能是Dkk蛋白介导的拮抗作用的原因。 然而,我们发现第三个YWTD重复,但不是第一个重复结构域,是DKK1介导的拮抗作用所必需的。 相反,我们发现G171V突变破坏了LRP5与Mesd的相互作用,Mesd是共受体转运到细胞表面所需的LRP5 / 6的伴侣蛋白,导致细胞表面上较少的LRP5分子。 尽管细胞表面LRP5分子水平的降低导致旁分泌范例中Wnt信号传导的降低,但突变似乎不影响共表达Wnt在自分泌范式中的活性。 连同观察到成骨细胞产生自分泌的正常Wnt,Wnt7b,并且该骨细胞产生旁分泌的Dkk1,我们认为G171V突变可能通过减少旁分泌Dkk1靶向拮抗的数目而引起成骨细胞中Wnt活性的增加,而不影响 自分泌Wnt的活性。
    • 8. 发明申请
    • Sclerostin and the inhibition of WNT signaling and bone formation
    • 硬皮蛋白和抑制WNT信号和骨形成
    • US20120115787A9
    • 2012-05-10
    • US11084668
    • 2005-03-18
    • Dianqing WuXiaofeng Li
    • Dianqing WuXiaofeng Li
    • A61K38/17
    • G01N33/6893G01N33/6887G01N2500/00G06F19/12
    • The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass (HBM). In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt coreceptor LRP5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transducing canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at the late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the HBM phenotype associated with the loss of sclerostin may at least in part be attributed to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism.
    • SOST基因产物硬化蛋白的丧失导致以高骨量(HBM)为特征的硬皮病。 在本报告中,我们发现硬皮蛋白可以拮抗人类胚胎肾A293细胞和小鼠成骨细胞MC3T3细胞中的典型Wnt信号。 这种硬脂蛋白介导的拮抗作用可以通过Wnt共同受体LRP5的过度表达来逆转。 此外,我们发现硬骨素与LRP5以及LRP6结合,并鉴定出LRP5的前两个YWTD-EGF重复结构域负责结合。 虽然这两个重复结构域是转导规范Wnt信号所必需的,但是典型的Wnt似乎没有与硬皮蛋白竞争结合LRP5。 在原发性颅骨成骨细胞分化过程中,考察了sclerostin和Wnt7b(一种自分泌标准Wnt)的表达,表明硬骨素在成骨细胞分化后期表达,与成骨标志物骨钙素表达相符,Wnt7b表达后表达。 鉴于许多证据表明典型的Wnt信号传导刺激成骨,我们认为与硬化蛋白的丧失有关的HBM表型可能至少部分归因于由于硬骨素介导的Wnt拮抗作用降低导致的典型Wnt信号传导的增加。
    • 9. 发明申请
    • Sclerostin and the inhibition of WNT signaling and bone formation
    • US20060030523A1
    • 2006-02-09
    • US11084668
    • 2005-03-18
    • Dianqing WuXiaofeng Li
    • Dianqing WuXiaofeng Li
    • A61K38/17
    • G01N33/6893G01N33/6887G01N2500/00G06F19/12
    • The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass (HBM). In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt coreceptor LRP5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transducing canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at the late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the HBM phenotype associated with the loss of sclerostin may at least in part be attributed to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism.